Ledipasvir-Sofosbuvir in Renal Disease

ERCHIVES-Renal

Ledipasvir-Sofosbuvir in Renal Disease
ERCHIVES-Renal: Study Design

ERCHIVES-Renal Study Design

- **Design**: Retrospective observational cohort review in Veterans Administration system to determine the effectiveness and safety of HCV treatment in persons with renal disease using two regimens: (1) ledipasvir-sofosbuvir, with or without ribavirin, and (2) ombitasvir-paritaprevir-ritonavir and dasabuvir, with or without ribavirin

- **Entry Criteria**
  - Chronic HCV genotype 1-6 (most with genotype 1)
  - Baseline chronic kidney disease (CKD stage 1-5 included)
  - Compensated cirrhosis allowed
  – Persons with HIV were excluded

- **End-Points**: Primary = SVR12, treatment completion, and safety
Ledipasvir-Sofosbuvir in Renal Disease
ERCHIVES-Renal: Results

ERCHIVES-Renal: Ledipasvir-Sofosbuvir in Chronic Kidney Disease

**Ledipasvir-Sofosbuvir in Renal Disease**

**ERCHIVES-Renal: Results**

**ERCHIVES-Renal: Ledipasvir-Sofosbuvir in Chronic Kidney Disease**

<table>
<thead>
<tr>
<th>CKD Stage</th>
<th>Grade 3/4 Anemia</th>
<th>Ledipasvir-Sofosbuvir</th>
<th>Ledipasvir-Sofosbuvir + Ribavirin</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-2</td>
<td>1.1</td>
<td>83/7630</td>
<td>47/3294</td>
</tr>
<tr>
<td>3</td>
<td>3.2</td>
<td>43/1345</td>
<td>35/479</td>
</tr>
<tr>
<td>4-5</td>
<td>9.7</td>
<td>10/103</td>
<td>3/30</td>
</tr>
</tbody>
</table>

**Conclusions:** “Ledipasvir-sofosbuvir and Ombitasvir-paritaprevir-ritonavir plus dasabuvir achieved high SVR rates in chronic kidney disease population. Treatment completion rates were lower than expected. A decline in eGFR and development of anaemia were observed in a substantial proportion of persons, but the clinical implications remain unclear.”

**Source:** Butt AA, et al. Aliment Pharmacol Ther. 2018;48:35-43